sur OXURION (EBR:OXUR)
Oxurion's Exagis Platform Gains Major Market Validation with Pierre Fabre Laboratories
Oxurion NV, a biopharmaceutical company based in Leuven, Belgium, announced that Pierre Fabre Laboratories has adopted its Exagis clinical data management platform. Developed by Oxurion's subsidiary Axiodis CRO, Exagis represents a significant commercial success for the company.
The platform, originally created to meet stringent data management standards, has evolved into a comprehensive Clinical Data Management System (CDMS). Its modular and scalable nature allows it to adapt to various clinical study configurations and organizational needs, serving biotech companies and large pharmaceutical groups alike.
Aline Stennevin of Pierre Fabre Dermo-Cosmétique praised Exagis for its operational efficiency and regulatory compliance. This collaboration underscores Oxurion's strategy to position Exagis as a core software asset in the industry.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION